Coelho RC, Abreu PDP, Monteiro MR, et al. - Given the activity of fluorouracil (FU) bolus, the PFL protocol, a chemotherapy regimen combining cisplatin, FU bolus, and leucovorin, was incorporated at the Brazilian National Cancer Institute as hospitalization or infusion pumps are not required in this schedule. This study aims to evaluate the outcomes of PFL in the first-line setting for patients with advanced GC. Researchers here examined the outcomes of PFL in the first-line setting for patients with advanced gastric cancer (GC). In this retrospective cohort study, they appraised patients with advanced GC who underwent treatment in the first-line setting with cisplatin 80 mg/m² on day 1 and FU bolus 400 mg/m² plus leucovorin 20 mg/m² on days 1, 8, 15, and 22 every 4 weeks, from January 2008 to December 2014. Among 109 enrolled patients, the median number of cycles provided per patient was four (one to 11). In 6.4%, complete responses were achieved and in 14.7%, partial responses were reported. They reported median progression-free survival of 6.3 months and median overall survival of 8.3 months. Outcomes support the activity of PFL in advanced GC and indicate its possible value as an alternative for FU continuous infusion protocols in institutions with limited resources and/or low budget, which is the reality in many nations all over the world.